- Quality Assurance: AI-assisted GMP decisions still require documented human review and clear Quality Unit accountability.
- Validation / CSV: Model validation alone may not be enough; teams also need evidence that users understand AI limitations, failure modes, and escalation rules.
- Regulatory / Digital Quality: As AI enters regulated workflows, companies need stronger traceability, role-based qualification, and documented oversight to support inspection readiness.
Pharma Is Spending More on AI But Qualification May Be the Missing Link
Pharma investment in AI is rising fast, but the expected gains have not followed at the same pace. The analysis notes that global corporate AI investment reached $252.3 billion in 2024, while McKinsey has yet to see meaningful industry-wide improvements in development timelines or clinical success rates.
Brian Drapeau argues that the gap may come from a step pharma already understands well: qualification. Companies validate equipment and processes, train users, and document competency. However, many AI programs have focused more on model performance than on whether users understand the system’s limits, failure modes, and appropriate use.
That gap becomes critical when AI output influences a GMP record or regulated decision.
FDA Warning Letter Shows What Happens When Human Oversight Fails
FDA’s April 2, 2026 Warning Letter to Purolea Cosmetics Lab put a clear compliance issue around AI use into focus. The company had used AI agents to help create drug specifications, procedures, and master production records, but FDA stressed that the Quality Unit still had to review those outputs for accuracy and CGMP compliance.
The message is straightforward: AI does not replace existing GMP accountability. When AI contributes to regulated documents or decisions, human review and Quality Unit oversight still apply under 21 CFR 211.22(c).
The table below shows how this finding translates into practical risks, required controls, and evidence for key pharma functions.
| Role | Main risk | Needed response | Evidence | Timing |
|---|---|---|---|---|
|
QA / Quality Unit |
Unreviewed AI output enters GMP records |
Define human review and approval |
SOPs and approval records |
Before routine use |
|
Validation / CSV |
Model works, but users misunderstand its limits |
Add role-specific qualification |
Training and competency evidence |
Before deployment |
|
Regulatory / Digital Quality |
AI-assisted decisions lack traceability |
Define governance and escalation |
Decision records and governance documentation |
Throughout the lifecycle |
AI Qualification in Pharma Could Decide Whether Pilots Ever Scale
Drapeau argues that validating the model alone is not enough. Pharma companies also need users who understand what an AI system can do, where it can fail, and when human escalation is required.
The analysis also points to early-2026 survey data linking mature AI and data-literacy programs with higher reported ROI, although it stops short of claiming causation.
For pharma teams, the implication is practical: qualification, competency assessment, and documented human oversight should start with deployment, not after an AI pilot begins to scale.
What Pharma Teams Should Watch as AI Moves Deeper Into GxP
The next important signal will come from future inspection findings and warning letters. If regulators repeatedly challenge inadequate human oversight around AI-assisted GMP work, companies may need to formalize AI qualification much faster. At the same time, wider AI deployment will test whether structured workforce qualification can help promising pilots move into controlled, scalable pharmaceutical operations.
For pharmaceutical teams introducing AI or other computerized technologies into regulated workflows, Qualification and Validation for GMP-Regulated Systems provides hands-on support across qualification, validation and lifecycle compliance. Zamann Pharma can help teams strengthen validation structures and keep regulated systems controlled and inspection-ready as digital workflows evolve.
Source: Pharmtech.Com